Braeburn Pharmaceuticals Inc filed with U.S. regulators on Friday to raise up to $150 million in an initial public offering, seven months after its implant to treat opioid addiction was approved in the United States.

The U.S. Food and Drug Administration in May approved an implant to fight addiction to opioids, a class of drugs that includes prescription painkillers and heroin.

Braeburn said it is planning a full-scale commercial launch of the matchstick-sized implant, Probuphine, which it has developed along with Titan Pharmaceuticals Inc (TTNP.O).

READ FULL ARTICLE HERE